For a study, the consequences of Severe Acute Respiratory Failure In multiple case series and observational studies, coronavirus 2 (SARS-CoV-2) infection was linked to increasing motor and non-motor symptoms, as well as probably greater mortality in patients with advanced illness, comorbidities, and frailty. The issue of long-term sequelae in patients with coronavirus disease 2019 (COVID-19), also known as “long COVID,” arose over time, and the National Institute for Health and Care Excellence in the United Kingdom recently defined the “post–COVID-19 syndrome” as “signs and symptoms that develop during or after an infection consistent with COVID-19, persist for more than 12 weeks, and are not explained by an alternative diagnosis.” 

From the beginning of March 2020 until the present, researchers provided the incidence of post–COVID-19 syndrome in 27 patients with PD who were impacted by COVID-19 across multiple centers in the United Kingdom, Italy, Romania, and Mexico. Because certain post–COVID-19 symptoms may be part of the PD clinical phenomenology, they only considered symptoms to be part of the clinical manifestations of a post–COVID-19 syndrome if they developed after a confirmed SARS-CoV-2 infection or if they worsened a previously stable pre-existing symptom. Within the long-COVID spectrum, they also report on motor deterioration and higher levodopa equivalent daily dose needs. 

Researchers aimed at 23 (85.2%) of the individuals with Parkinson’s disease who experienced post–COVID 19 symptoms. The most common long-term effects of COVID-19 were worsening motor function (51.9%) and increased levodopa daily dose requirements (48.2%), followed by fatigue (40.7%), cognitive disturbances (22.2%), including “brain fog,” loss of concentration, and memory deficits, and sleep disturbances (22.2%), such as insomnia. These symptom complexes, in general, agree with the previous research on extended COVID in the general population. Surprisingly, the severity of COVID-19, as indicated by a history of hospitalization, did not appear to be a prerequisite for the development of a post–COVID-19 syndrome in individuals with Parkinson’s disease.